CN112592871A - Lactobacillus casei JYLC-374 and application thereof in product for improving male prostate - Google Patents
Lactobacillus casei JYLC-374 and application thereof in product for improving male prostate Download PDFInfo
- Publication number
- CN112592871A CN112592871A CN202110073009.5A CN202110073009A CN112592871A CN 112592871 A CN112592871 A CN 112592871A CN 202110073009 A CN202110073009 A CN 202110073009A CN 112592871 A CN112592871 A CN 112592871A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus casei
- jylc
- prostate
- hundred million
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000199866 Lactobacillus casei Species 0.000 title claims abstract description 100
- 235000013958 Lactobacillus casei Nutrition 0.000 title claims abstract description 100
- 229940017800 lactobacillus casei Drugs 0.000 title claims abstract description 100
- 210000002307 prostate Anatomy 0.000 title abstract description 26
- 238000004321 preservation Methods 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 238000009629 microbiological culture Methods 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 27
- 239000001963 growth medium Substances 0.000 claims description 21
- 229920001817 Agar Polymers 0.000 claims description 8
- 239000008272 agar Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 235000013618 yogurt Nutrition 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 235000015278 beef Nutrition 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 claims description 5
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 5
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 108010009004 proteose-peptone Proteins 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 239000002054 inoculum Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 239000003814 drug Substances 0.000 abstract description 18
- 208000017497 prostate disease Diseases 0.000 abstract description 13
- 230000006870 function Effects 0.000 abstract description 12
- 230000036039 immunity Effects 0.000 abstract description 10
- 241000186660 Lactobacillus Species 0.000 abstract description 7
- 229940039696 lactobacillus Drugs 0.000 abstract description 7
- 244000052616 bacterial pathogen Species 0.000 abstract description 5
- 230000002485 urinary effect Effects 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 14
- 229960003376 levofloxacin Drugs 0.000 description 14
- 206010060862 Prostate cancer Diseases 0.000 description 13
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 13
- 201000007094 prostatitis Diseases 0.000 description 13
- 230000027939 micturition Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000255601 Drosophila melanogaster Species 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- 229960003198 tamsulosin hydrochloride Drugs 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000000306 component Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000255588 Tephritidae Species 0.000 description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 101100262208 Drosophila melanogaster tub gene Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 229910001868 water Inorganic materials 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010018866 Haematospermia Diseases 0.000 description 1
- 208000008982 Hemospermia Diseases 0.000 description 1
- 101001014553 Homo sapiens MRG/MORF4L-binding protein Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 102100032521 MRG/MORF4L-binding protein Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000037209 prostate health Effects 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of microorganisms, in particular to lactobacillus casei JYLC-374 and application thereof in improving male prostate products, wherein the lactobacillus casei JYLC-374 belongs to the genus Lactobacillus, and the preservation number is as follows: CGMCC NO.18096, wherein the preservation unit is China general microbiological culture Collection center, the preservation date is 7 months and 8 days in 2019, and the classification name of the strains is Lactobacillus caseiLactobacillus casei(ii) a The food or/and the medicine containing the lactobacillus casei JYLC-374 have the functions of correcting the micro-ecological structure of the urinary system, reducing the number of pathogenic bacteria of the prostate, improving the immunity of the prostate system, improving the expression function of immune balance factors, effectively improving male prostate diseases, and reducing the medical cost, and have the advantages of quick curative effect, no side effect and high curative effect.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to lactobacillus casei JYLC-374 and application thereof in a product for improving male prostate.
Background
Lactobacillus casei belongs to the genus Lactobacillus (Lactobacillus), which is one of the probiotics and is resistant to the defense mechanisms of organisms, including enzymes in the oral cavity, low pH in gastric juice, bile acids in the small intestine, and the like. Therefore, the lactobacillus casei can survive in a large amount in intestinal tracts after entering a human body, and has the effects of regulating intestinal flora balance, promoting digestion and absorption of the human body and the like. Meanwhile, the lactobacillus casei has the functions of efficiently reducing blood pressure and cholesterol, promoting cell division, generating antibody immunity, enhancing human immunity, preventing cancer, inhibiting tumor growth and the like; also has the beneficial health effects of relieving lactose intolerance and allergy. The lactobacillus casei has obvious probiotic effects on host nutrition, immunity, disease prevention and the like, and is more and more the focus of research, development and production of people.
Prostate diseases are common diseases of adult men, usually refer to prostatitis, prostatic hyperplasia, prostate cancer and the like, the incidence rate of prostate diseases is in a rapid rising trend in recent years, and the prostate diseases are often manifested by frequent micturition, urgent micturition, odynuria, hematuria, dysuria, urinary incontinence, bifurcations of urinary lines, dribbling after urination, increased times of nocturia, white dribbling after urination or defecation, and can be complicated with sexual dysfunction, including hyposexuality, premature ejaculation, ejaculation pain in ejaculation, erectile dysfunction and impotence, even secondary upper urinary tract damage, systemic symptoms and the like.
There is a huge and very diverse association between intestinal microorganisms and prostate function. The incidence of prostate cancer (PCa) in IBD (inflammatory bowel disease) patients was 4.4%, while the control group was 0.65%, HR = 4.84. Various pathogenic bacteria colonized in an intestinal system can destroy an epidermal barrier, directly trigger inflammatory reaction, cause prostatitis/chronic pelvic pain syndrome and finally develop prostate cancer. Once the prostate is in a pathological state, the composition of the prostate fluid changes, which indirectly induces the proliferation of intestinal pathogens. Auxiliary treatment schemes for prostate diseases that target the intestinal micro-ecosystem have become a clinical focus.
At present, the prostate disease is generally treated mainly by comprehensive treatment such as medicine, physical therapy and the like, the cost is high, the curative effect is slow, the medicine treatment of' three-component medicine is harmful to the body and generates toxic and side effects, the lactobacillus casei is not reported to be used for improving the prostate disease, and the probiotics resources which have exact treatment or improvement effects on the prostate disease in China are very deficient.
Disclosure of Invention
The invention solves the problems that the cost is high when the male prostate disease is improved, the curative effect is slow, and the traditional Chinese medicine or western medicine generates toxic and side effects on human bodies, aiming at solving the problem of the lack of probiotic resources for improving the prostate disease; the lactobacillus casei JYLC-374 has the functions of correcting the micro-ecological structure of a urinary system, reducing the number of prostate pathogenic bacteria, improving the immunity of a prostate system, improving the expression function of an immune balance factor and effectively improving male prostate diseases.
In view of the above problems, the invention aims to provide lactobacillus casei JYLC-374, the strain number of the lactobacillus casei is JYLC-374, and the preservation number is as follows: CGMCC NO.18096, the preservation unit is China general microbiological culture Collection center, the preservation date is 7 months and 8 days in 2019, and the preservation place isSite: west road No.1, north chen, chaoyang district, beijing, zip code: 100101 the classification of the strains is named as Lactobacillus caseiLactobacillus casei.The classification unit is as follows: lactobacillus casei.
Further, the lactobacillus casei JYLC-374 is separated from fermented yoghourt at home of farmers in the inner Mongolia Teqi.
Further, the second purpose of the invention is to apply the lactobacillus casei JYLC-374 in preparing food or/and medicines.
Further, the food or/and the medicine has a preservation number of: lactobacillus casei JYLC-374 with CGMCC NO. 18096.
Furthermore, the food or/and the medicine have the application of improving the prostate of men.
Furthermore, the food or/and the medicine have the function of improving immunity.
Further, the food contains lactobacillus casei JYLC-374 bacterial powder.
Furthermore, the viable count of the lactobacillus casei JYLC-374 bacterial powder is more than or equal to 50 hundred million/g.
Furthermore, the viable count of the lactobacillus casei JYLC-374 bacterial powder is 50 hundred million/g, 150 hundred million/g, 250 hundred million/g, 500 hundred million/g or 1000 hundred million/g.
Further, the preparation method of the lactobacillus casei JYLC-374 bacterial powder comprises the following steps: inoculating lactobacillus casei JYLC-374 to a lactobacillus casei culture medium plate, carrying out aerobic culture at 37 ℃ for 24h, selecting a single colony with the diameter of more than 1.5mm, washing the single colony for 3 times by using PBS buffer solution, centrifuging, discarding the supernatant, and drying to obtain lactobacillus casei JYLC-374 bacterial powder.
Further, the inoculation amount of lactobacillus casei JYLC-374 was 1% by volume.
Further, the lactobacillus casei culture medium comprises 10g of casein peptone, 10g of beef extract, 5g of yeast powder, 5g of glucose, 5g of sodium acetate, 2g of diammonium citrate, 801 g of Tween and K2HPO4 2g、MgSO4.7H2O 0.2g、MnSO4.H2O 0.05g、CaCO320g of agar and 15g of agar, and steamingDistilled water 1.0L.
Furthermore, the food or/and the medicine containing lactobacillus casei JYLC-374 have the functions of correcting the micro-ecological structure of the urinary system and reducing the number of prostate pathogenic bacteria.
Furthermore, the food or/and the medicine containing the lactobacillus casei JYLC-374 have the functions of improving the immunity of a prostate system and improving the expression of an immune balance factor.
The invention has the beneficial effects that:
1. the lactobacillus casei JYLC-374 provided by the invention is obtained by separating and screening domestic fermented yoghourt of a farmer in the inner Mongolia Teqi, belongs to the genus lactobacillus casei by identification, is named as JYLC-374, and has the preservation number: CGMCC NO.18096, wherein the preservation unit is China general microbiological culture Collection center, the preservation date is 7/8/2019, and the preservation address is as follows: west road No.1, north chen, chaoyang district, beijing, zip code: 100101 the classification of the strains is named as Lactobacillus caseiLactobacillus caseiMicroorganism (strain): lactobacillus casei (Lactobacillus casei) has classification units as follows: lactobacillus casei; the food or/and the medicine containing the lactobacillus casei JYLC-374 have the functions of correcting the micro-ecological structure of the urinary system, reducing the number of pathogenic bacteria of the prostate, improving the immunity of the prostate system and improving the expression of immune balance factors.
2. The food or/and the medicine containing lactobacillus casei JYLC-374 provided by the invention can effectively improve male prostate diseases, avoid the pain of patients caused by the current surgical treatment, simultaneously avoid the side effect caused by western medicine treatment, have good effect of improving the male prostate diseases, have no side effect and reduce the treatment cost.
Drawings
FIG. 1 is fingerprint spectrum of Lactobacillus casei JYLC-374 and model strain (CICC-6117);
FIG. 2 is a graph of the survival curves of female Drosophila melanogaster after feeding Lactobacillus casei JYLC-374 and CICC-6117;
FIG. 3 shows the expression of male drosophila prostate health related genes after feeding Lactobacillus casei JYLC-374 and CICC-6117 to drosophila.
The specific implementation mode is as follows:
for better understanding of the present invention, the technical solution of the present invention will be described in detail with specific examples, but the present invention is not limited thereto.
The lactobacillus casei JYLC-374 provided by the invention is obtained by separating and screening domestic fermented yoghourt of a farmer in the inner Mongolia Teqi, belongs to the genus lactobacillus casei by identification, is named as JYLC-374, and has the preservation number: CGMCC NO.18096, wherein the preservation unit is China general microbiological culture Collection center, the preservation date is 7/8/2019, and the preservation address is as follows: west road No.1, north chen, chaoyang district, beijing, zip code: 100101 the classification of the strains is named as Lactobacillus caseiLactobacillus caseiMicroorganism (strain): lactobacillus casei (Lactobacillus casei) has classification units as follows: lactobacillus casei;
the preservation number of the model strain used in the invention is CICC-6117, and the model strain is purchased from China center for culture preservation and management of industrial microorganisms;
the bacterial genome extraction kit (DP 302) is purchased from Tiangen Biochemical technology (Beijing) Co., Ltd, and has a commodity number of DP 302;
LIVE/DEAD BacLight bacterial cell activity assay kit purchased from seimer feishell science and technology (china) ltd, cat #: l7007;
the real-time fluorescent quantitative PCR Kit is purchased from Qiajie biotechnology Qiagen Quanntinova SYBR Green PCR Kit, Cat No.: 208054, respectively;
the components of the improved MRS culture medium plate are 10g of casein peptone, 10g of beef extract, 5g of yeast powder, 5g of glucose, 5g of sodium acetate, 2g of diammonium citrate, 801 g of Tween and K2HPO4 2g、MgSO4.7H2O 0.2g、MnSO4.H2O 0.05g、CaCO320g of agar, 15g of agar, 1.0L of distilled water and hydrochloric acid for adjusting the pH value to 6.2 +/-0.2.
The liquid MRS culture medium comprises components of casein peptone 10g, beef extract 10g, yeast powder 5g, and,5g of glucose, 5g of sodium acetate, 2g of diammonium citrate, 801 g of Tween and K2HPO4 2g、MgSO4.7H2O 0.2g、MnSO4.H2O 0.05g、CaCO320g, 1.0L of distilled water and hydrochloric acid for adjusting the pH value to 6.2 +/-0.2.
Gastric juice simulated medium was purchased from: PERFEMIKER, item number: PM 10004;
the lactobacillus casei culture medium comprises 10g of casein peptone, 10g of beef extract, 5g of yeast powder, 5g of glucose, 5g of sodium acetate, 2g of diammonium citrate, 801 g of Tween and K2HPO4 2g、MgSO4.7H2O 0.2g、MnSO4.H2O 0.05g、CaCO320g of agar, 15g of agar and 1.0L of distilled water.
Example 1
The invention provides lactobacillus casei JYLC-374
1. Strain screening
1) Sample source
Selecting self-fermented yoghourt of inner Mongolia Teqi farmer
2) Strain preparation
Adding 0.7 percent of saline with the concentration of 0.9 percent into sample yoghourt according to the volume percentage, fully shaking and uniformly mixing to form mixed liquid, taking 1 percent of the mixed liquid according to the volume percentage under an anaerobic condition, streaking and inoculating the mixed liquid onto an improved MRS culture medium plate, carrying out anaerobic culture for 48 hours at 37 ℃, selecting a single bacterial colony with the diameter of 1.5mm, inoculating the single bacterial colony with the diameter of 1.5mm into the improved MRS culture medium plate, carrying out anaerobic culture for 72 hours at 37 ℃ until the character is stable, namely the physiological state of bacteria is stable, then picking the single bacterial colony to inoculate in a liquid MRS culture medium, carrying out anaerobic culture for 18 hours at 37 ℃, and obtaining a culture bacterial liquid, wherein the JYLC-374 name is a JYLC;
2. identification of strains
1) Taking 5ml of culture solution into an aseptic centrifuge tube, washing for 2 times by using PBS buffer solution, centrifuging, extracting genome DNA by using a bacterial genome extraction kit (DP 302) to obtain strain DNA, and averagely dividing the strain DNA into two parts, namely strain DNA-A and strain DNA-B;
2) using universal primers
27f ：5'-AGAGTTTGATCCTGGCTCAG-3'；
1492r ：5-'CTACGGCTACCTTGTT-3'；
3) Identification of species (systematics)
Adding 38 mu L of deionized water, 5 mu L of Buffer, 1 mu L of upstream primer, 1 mu L of downstream primer, 1 mu L of dNTP (10 mM), 0.5 mu L of Taq enzyme and 0.5 mu L of strain DNA-A into a 50 mu L LPCR amplification system, and uniformly mixing to form a PCR amplification solution;
setting PCR reaction parameters: A. pre-denaturation at 94 ℃ for 5 min; B. 30 cycles: denaturation at 94 ℃ for 30s, annealing at 55 ℃ for 30s, and extension at 72 ℃ for 30 s; C. fully extending for 10min at 72 ℃, and finishing the reaction to obtain a PCR product I;
thirdly, the PCR product I is sent to the company Limited in the Biotechnology engineering (Shanghai) to be sequenced, the full length of 16S rDNA is detected by sequencing, the sequenced Gene sequence is subjected to blast comparison with related sequences in Gene Bank to carry out homology comparison, and the Gene sequence in the application is found to be compared with lactobacillus casei recorded by NCBILactobacillus caseiThe similarity of the sequences reaches 99 percent, and the strains are identified as lactobacillus casei homologous strains and are named as JYLC-374;
4) identification of species (Gene map)
RAPD amplification is carried out on the strain DNA-B by taking the strain DNA-B as a template and taking the bacterial universal primer 5'-GACGGATCAG-3' as an amplification primer to prepare an amplification product II, and then the amplification product II is detected by a QIAGEN QIAxcel capillary electrophoresis instrument;
wherein the result of RAPD amplification is shown in figure 1 by using the deposit number CICC-6117 as a model strain;
it is found from fig. 1 that: the lactobacillus casei JYLC-374 has a different genome structure from a model strain (CICC-6117) and belongs to different strains in the same bacterial species.
Example 2
Gastric acid barrier permeability of lactobacillus casei JYLC-374
Setting a lactobacillus casei JYLC-374 group and a CICC-6117 group, wherein the CICC-6117 group takes CICC-6117 as a control strain;
taking lactobacillus casei JYLC-374 as an example to prepare a lactobacillus casei JYLC-374 culture solution, the steps are as follows: inoculating 1mg of lactobacillus casei JYLC-374 into 10ml of gastric juice simulated culture medium, and culturing for 2 hours to obtain a lactobacillus casei JYLC-374 culture solution;
according to the preparation method of the lactobacillus casei JYLC-374 culture solution, CICC-6117 culture solution is prepared according to the method;
3ml of culture solution in each group is taken respectively, the cell activity of the culture solution in each group is measured and dyed by a LIVE/DEAD Baclight bacterial cell activity measuring kit, meanwhile, the dyed culture solution strain is observed and counted under an Olympus BX51 epifluorescence microscope, and DEAD cells and LIVE cells are recorded;
viability = viable cell count/initial viable cell count × 100%
Results and conclusions: the gastric acid barrier tolerance test result shows that the survival rate of the lactobacillus casei JYLC-374 in a gastric acid simulated culture medium with the pH value of 3.0 reaches 92.12 percent after 2 hours, and the survival rate of the lactobacillus casei JYLC-6117 is 71.9 percent, so that the survival rate of the lactobacillus casei JYLC-374 in the gastric acid barrier and intestinal tract is higher than that of the lactobacillus casei JYLC-6117.
Example 3
Auxiliary improvement effect of lactobacillus casei JYLC-374 on prostate cancer
The method is characterized in that drosophila melanogaster of prostate cancer mutants is used as a test sample to simulate prostatitis patients induced by prostatitis, after lactobacillus casei JYLC-374 viable bacteria are added into a culture medium, the promotion effect of lactobacillus casei JYLC-374 on the life of the drosophila melanogaster of the prostate cancer is detected through tests such as 'full life cycle life prolonging', 'tumor necrosis factor', 'inflammation promotion factor expression quantity', 'balanced immune factor expression detection', and the like, and the CICC-6117 is used as a control strain;
test samples: the drosophila melanogaster of the prostatic cancer mutant is purchased from the resource center of Indiana Blomointon drosophila melanogaster of America, RNAi is adopted to construct the mutant drosophila melanogaster and simulate MRGBP related to prostatic cancerNIG.13746RAn allelic mutation. Biological functions: a drosophila prostate cancer pathological model;
preparing a basal medium containing lactobacillus casei JYLC-374: uniformly mixing 2ml of improved MRS liquid culture medium and 20 mu g of lactobacillus casei JYLC-374 bacterial powder to prepare a basic culture medium containing lactobacillus casei JYLC-374, wherein the viable count of the lactobacillus casei JYLC-374 bacterial powder is 50 hundred million/g;
basic culture medium containing CICC-6117: uniformly mixing 2ml of improved MRS liquid culture medium and 20 mu g of CICC-6117 bacterial powder to prepare a basic culture medium containing CICC-6117, wherein the viable count of the CICC-6117 bacterial powder is 50 hundred million/g;
the test method comprises the following steps: the drosophila melanogaster with male prostate cancer is respectively placed in a drosophila melanogaster tube of 2ml of basic culture medium containing lactobacillus casei JYLC-374 and a drosophila melanogaster tube of basic culture medium containing CICC-6117, each tube has 100, and the culture conditions are as follows: the temperature is 25 ℃, the light and dark rhythm is alternated (namely, the culture is carried out by adopting 12h of visible light within one day and the culture is carried out in a dark place for 12 h), the humidity is 60 percent, the basic culture medium is replaced every 5 days, the death number of the fruit flies is observed and recorded every day, and simultaneously, after the fruit flies are fed for 60 days, the fluorescence quantitative PCR is carried out on the fruit flies by a real-time fluorescence quantitative PCR kit, wherein the gene name of a primer is eiger、Rp49、Upd1、bap180The primer sequence (see table 1) of (1), expression of related genes such as tumor necrosis factor and inflammation marker, and determining the life-span promoting effect of lactobacillus casei JYLC-374 on drosophila melanogaster with prostate cancer tumor, the results are shown in table 2, fig. 2 and fig. 3;
TABLE 1 fluorescent quantitative PCR detection of the genes involved and primer pairs
TABLE 2 Drosophila Life Curve Log-rank test under two probiotic feeding conditions
Results and conclusions: the lactobacillus casei JYLC-374 related to the invention can obviously increase the life span (Log-rank test) of the prostate cancer mutant drosophilap= 0.0096), can significantly improve the 60-day survival rate of mutant drosophila melanogaster compared to the control strain cic-6117. The strain can remarkably improve the organism immunity of female drosophila melanogasterThe expression of the balance factors improves the cancer inhibition effect of the prostate cancer mutant drosophila on the whole organism layer; female fruit fly fed with Lactobacillus casei JYLC-374 strain, proinflammatory factor, compared to control groupeigerExhibits 2-fold down-regulation of expression (p <0.01) to prove that the bacterial strain has good treatment or improvement effect on the aseptic prostatitis by activating the immunity of the organism while reducing the colonization of harmful bacteria.
Example 4
Function of lactobacillus casei JYLC-374 in improving prostatitis
Preparation before the test: preparation of the microbial inoculum: adopting lactobacillus casei JYLC-374 bacterial powder and CICC-6117 bacterial powder;
randomly selecting 100 chronic prostatitis patients (diagnosed as chronic prostatitis, the age is 30-35 years old), randomly dividing into 2 groups, and dividing each group into 50 persons, namely lactobacillus casei JYLC-374 group and CICC-6117 control group;
the test method comprises the following steps: the lactobacillus casei JYLC-374 group orally takes lactobacillus casei JYLC-374 bacterial powder 3mg daily for 50 days continuously;
CICC-6117 control group orally takes CICC-6117 bacterial powder every day, 3mg every day, and continuously takes 50 days;
recording nighttime toileting times of each group of test members, counting morning brix rate (visit every 10 days, data recording) by using morning brix self-test strips, and simultaneously carrying out rectal digital examination and B-ultrasonic examination (prostate fluid sample submission) on each group of test members 1 day before the test begins; the results of digital rectal examination and B-ultrasonic examination (prostate fluid sample presentation) on day 1 after the end of the test were shown in Table 3
TABLE 3 statistics of prostate fluid test data for 50 days after taking micro-ecological preparation
(1) Calculating the short-term diarrhea rate according to the statistical data of patients with mild diarrhea within five days after taking;
(2) the sperm morphology improvement rate is calculated by taking the number of double-headed sperms and the ratio of hemospermia as the basis;
(3) the removal rate of mixed bacteria is calculated according to the culture result of prostatic fluid bacteria;
results and conclusions: the data show that after the lactobacillus casei JYLC-374 strain is taken for 50 days as a microecological preparation of a core component, the prostate fluid detection index of a reference volunteer is obviously improved, the red and white blood cell content is obviously reduced, the expression level of inflammatory factors and markers is reduced, harmful bacteria are obviously reduced, and the sperm morphology is improved. Meanwhile, the living quality of the test volunteers is obviously improved, the frequent micturition and odynuria symptoms are greatly improved, and male physical signs such as morning bok and the like are better improved. The above investigation data all take the model strain CICC-6117 as reference, and the statistical test result shows that the recovery effect of taking JYLC-374 to the male prostate function is obviously higher than that of the model strain CICC-6117.
Example 5
Lactobacillus casei JYLC-374 effect on improving prostate gland in men
Test group 1: adopting lactobacillus casei JYLC-374 bacterial powder, wherein the viable count is 100 hundred million/g;
control group 1: tamsulosin hydrochloride sustained-release capsules and levofloxacin tablets (both the tamsulosin hydrochloride sustained-release capsules and the levofloxacin tablets are purchased from drugstores, the tamsulosin hydrochloride sustained-release capsule manufacturer is Hangzhou kang Enbei pharmaceutical Co., Ltd., the specification is 0.2mg, the levofloxacin tablet manufacturer is the first Sanshu pharmaceutical (Beijing) Co., Ltd., the specification is 0.5 mg)
Control group 2: levofloxacin tablets + pule ' an tablets (prostaglandins) (both levofloxacin tablets and pule ' an tablets are purchased from drugstores, the levofloxacin tablet manufacturer is the first three-component pharmaceutical (Beijing) company Limited and has the specification of 0.5mg, the pule ' an tablet manufacturer is Zhejiang Kangbei pharmaceutical company Limited and has the specification of 0.57g 60s (tablets) (OTC))
The number of the test persons in each group: 50 persons/group
Symptoms are: each group of patients is type I prostatitis patients with age of 30-35 years, and the clinical symptoms of type I prostatitis patients are fever, fatigue, weakness, frequent micturition and urgent micturition;
the test contents are as follows: test group 1 was taken half an hour after breakfast and supper every day at a dose of 2g/50kg with warm water;
the tamsulosin hydrochloride sustained-release capsules and the levofloxacin tablets in the control group 1 are taken according to the usage amount on the medicine box;
the pulean tablet (Qianlikang) and levofloxacin tablet in the control group 2 are taken according to the usage amount on the medicine box;
the test group 1, the control group 1 and the control group 2 are all continuously taken for 30 days, the cure rate in 10 days, 20 days and 30 days, the symptoms and the side effects of the patients are recorded respectively, and the details are shown in a table 4;
the calculation method of the cure rate comprises the following steps: cure rate = (number of cure/number of test) × 100%
Table 4: the detection indexes of the test group 1, the control group 1 and the control group 2 for improving the male prostate are determined
As can be seen from Table 4, the Lactobacillus casei JYLC-374 bacterial powder has obvious effects on improving and treating or improving the type I prostatitis and has no side effect.
Example 6
Lactobacillus casei JYLC-374 effect on improving prostate gland in men
Test group 2: adopting lactobacillus casei JYLC-374 bacterial powder, wherein the viable count is 100 hundred million/mL;
control group 3: tamsulosin hydrochloride sustained-release capsules and levofloxacin tablets (both the tamsulosin hydrochloride sustained-release capsules and the levofloxacin tablets are purchased from drugstores, the tamsulosin hydrochloride sustained-release capsule manufacturer is Hangzhou kang Enbei pharmaceutical Co., Ltd., the specification is 0.2mg, the levofloxacin tablet manufacturer is the first Sanshu pharmaceutical (Beijing) Co., Ltd., the specification is 0.5 mg)
Control group 4: levofloxacin tablets + pule ' an tablets (prostaglandins) (both levofloxacin tablets and pule ' an tablets are purchased from drugstores, the levofloxacin tablet manufacturer is the first three-component pharmaceutical (Beijing) company Limited and has the specification of 0.5mg, the pule ' an tablet manufacturer is Zhejiang Kangbei pharmaceutical company Limited and has the specification of 0.57g 60s (tablets) (OTC))
The number of the test persons in each group: 50 persons/group
Symptoms are: the clinical symptoms of the type III prostatitis of each group are fever, fatigue, weakness, frequent micturition, urgent micturition, increased nocturia, abnormal urination, premature ejaculation and impotence;
the test content is the same as that of the example 5, the cure rates of the test group 2, the control group 3 and the control group 4 at 10 days, 20 days and 30 days, the symptoms and the side effects of the medicine are recorded respectively, and the details are shown in a table 5;
the calculation method of the cure rate comprises the following steps: cure rate = (number of cure/number of test) × 100%
Table 5: the detection indexes of the test group 2, the control group 3 and the control group 4 for improving the male prostate are measured
As can be seen from Table 5, the Lactobacillus casei JYLC-374 bacterial powder has obvious effect on improving or treating the type III prostatitis and has no side effect.
Sequence listing
<110> Shandong Zhongke Jiayi bioengineering Co., Ltd
<120> Lactobacillus casei JYLC-374 and application thereof in products for improving male prostate
<130> 2021.1.1
<160> 11
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1498
<212> DNA
<213> Lactobacillus casei (Lactobacillus casei)
<400> 1
gatgacgctg gcggcgtgcc taatacatgc aagtcgaacg agttctcgtt gatgatcggt 60
gcttgcaccg agattcaaca tggaacgagt ggcggacggg tgagtaacac gtgggtaacc 120
tgcccttaag tgggggataa catttggaaa cagatgctaa taccgcatag atccaagaac 180
cgcatggttc ttggctgaaa gatggcgtaa gctatcgctt ttggatggac ccgcggcgta 240
ttagctagtt ggtgaggtaa tggctcacca aggcgatgat acgtagccga actgagaggt 300
tgatcggcca cattgggact gagacacggc ccaaactcct acgggaggca gcagtaggga 360
atcttccacc aatggacgca agtctgatgg agcaacgccg cgtgagtgaa gaaggctttc 420
gggtcgtaaa actctgttgt tggagaagaa tggtcggcag agtaactgtt gtcggcgtga 480
cggtatccaa ccagaaagcc acggctaaac tacgtgccag cagccgcggt aatacgtagg 540
tggcaagcgt tatccgggat ttattgggcg taaagcgagc gcaggcggtt ttttaagtct 600
gatgtgaaag ccctcggctt aaccgaggaa gcgcatcgga aactgggaaa cttgagtgca 660
gaagaggaca gtggaactcc atgtgtagcg gtgaaatgcg tagatatatg gaagaacacc 720
agtggcgaag gcggctgtct ggtctgtaac tgacgctgag gctcgaaagc atgggtagcg 780
aacaggatta gataccctgg tagtccatgc cgtaaacgat gaatgctagg tgttggaggg 840
tttccgccct tcagtgccgc agctaacgca ttaagcattc cgcctgggga gtacgaccgc 900
aaggttgaaa ctcaaaggaa ttgacggggg cccgcacaag cggtggagca tgtggtttaa 960
ttcgaagcaa cgcgaagaac cttaccaggt cttgacatct tttgatcacc tgagagatca 1020
ggtttcccct tcgggggcaa aatgacaggt ggtgcatggt tgtcgtcagc tcgtgtcgtg 1080
agatgttggg ttaagtcccg caacgagcgc aacccttatg actagttgcc agcatttagt 1140
tgggcactct agtaagactg ccggtgacaa accggaggaa ggtggggatg acgtcaaatc 1200
atcatgcccc ttatgacctg ggctacacac gtgctacaat ggatggtaca acgagttgcg 1260
agaccgcgag gtcaagctaa tctcttaaag ccattctcag ttcggactgt aggctgcaac 1320
tcgcctacac gaagtcggaa tcgctagtaa tcgcggatca gcacgccgcg gtgaatacgt 1380
tcccgggcct tgtacacacc gcccgtcaca ccatgagagt ttgtaacacc cgaagccggt 1440
ggcgtaaccc ttttagggag cgagccgtct aaggtgggac aaatgattag gggaagtc 1498
<210> 2
<211> 20
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 2
<210> 3
<211> 16
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 3
ctacggctac cttgtt 16
<210> 4
<211> 20
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 4
<210> 5
<211> 20
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 5
<210> 6
<211> 23
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 6
gacgcttcaa gggacagtat ctg 23
<210> 7
<211> 18
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 7
aaacgcggtt ctgcatga 18
<210> 8
<211> 19
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 8
agacagccgt caaccagac 19
<210> 9
<211> 20
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 9
gcttcaaacg cttgttcatc 20
<210> 10
<211> 20
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 10
<210> 11
<211> 20
<212> DNA
<213> Artificial Synthesis (Artificial Synthesis)
<400> 11
Claims (9)
1. The lactobacillus casei JYLC-374 is characterized in that the strain number of the lactobacillus casei is JYLC-374, and the preservation number is as follows: CGMCC NO.18096, wherein the preservation unit is China general microbiological culture Collection center, and the preservation date is 7 months and 8 days in 2019.
2. The lactobacillus casei JYLC-374 according to claim 1, wherein the lactobacillus casei JYLC-374 is isolated from self-fermented yogurt of the inner mongolian jateqi farmer.
3. Use of lactobacillus casei JYLC-374 according to claim 1 in the preparation of a food or/and pharmaceutical product.
4. The use according to claim 3, wherein the food or/and pharmaceutical product comprises Lactobacillus casei JYLC-374 bacterial powder.
5. The use of claim 4, wherein the viable count of the lactobacillus casei JYLC-374 bacterial powder is more than or equal to 50 hundred million/g.
6. The use of claim 5, wherein the viable count of the Lactobacillus casei JYLC-374 bacterial powder is 50 hundred million/g, 150 hundred million/g, 250 hundred million/g, 500 hundred million/g or 1000 hundred million/g.
7. The use of claim 4 or 5, wherein the lactobacillus casei JYLC-374 bacterial powder is prepared by the following steps: inoculating lactobacillus casei JYLC-374 to a lactobacillus casei culture medium plate, carrying out aerobic culture at 37 ℃ for 24h, selecting a single colony with the diameter of more than 1.5mm, washing the single colony for 3 times by using PBS buffer solution, centrifuging, discarding the supernatant, and drying to obtain lactobacillus casei JYLC-374 bacterial powder.
8. Use according to claim 7, characterized in that the lactobacillus casei JYLC-374 inoculum size is 1% by volume.
9. The use of claim 7, wherein the lactobacillus casei culture medium comprises casein peptone 10g, beef extract 10g, yeast powder 5g, glucose 5g, sodium acetate 5g, diammonium citrate 2g, Tween 801 g, K2HPO42g、MgSO4.7H2O 0.2g、MnSO4.H2O 0.05g、CaCO320g of agar, 15g of agar and 1.0L of distilled water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110073009.5A CN112592871B (en) | 2021-01-20 | 2021-01-20 | Lactobacillus casei JYLC-374 and application thereof in product for improving male prostate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110073009.5A CN112592871B (en) | 2021-01-20 | 2021-01-20 | Lactobacillus casei JYLC-374 and application thereof in product for improving male prostate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112592871A true CN112592871A (en) | 2021-04-02 |
| CN112592871B CN112592871B (en) | 2021-11-05 |
Family
ID=75207810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110073009.5A Active CN112592871B (en) | 2021-01-20 | 2021-01-20 | Lactobacillus casei JYLC-374 and application thereof in product for improving male prostate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112592871B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113444675A (en) * | 2021-09-01 | 2021-09-28 | 山东向日葵生物工程有限公司 | Lactobacillus casei SF-L-12, plant beverage thereof and application thereof in ovary maintenance |
| CN115181711A (en) * | 2022-09-14 | 2022-10-14 | 中国农业科学院北京畜牧兽医研究所 | Human milk bacillus LHM11, microbial inoculum and application |
| CN115181712A (en) * | 2022-09-14 | 2022-10-14 | 中国农业科学院北京畜牧兽医研究所 | Lactobacillus johnsonii LJM20 and microbial inoculum and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101333505A (en) * | 2007-06-26 | 2008-12-31 | 内蒙古农业大学 | Applications of lactobacillus casei for antioxidation |
-
2021
- 2021-01-20 CN CN202110073009.5A patent/CN112592871B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101333505A (en) * | 2007-06-26 | 2008-12-31 | 内蒙古农业大学 | Applications of lactobacillus casei for antioxidation |
Non-Patent Citations (3)
| Title |
|---|
| LANA S. ROSA等: "Antiproliferative and apoptotic effects of probiotic whey dairy beverages in human prostate cell lines", 《FOOD RESEARCH INTERNATIONAL》 * |
| ZHANG,J: "Lactobacillus casei strain c47 16S ribosomal RNA gene, partial sequence", 《GENBANK DATABASE》 * |
| 迟珺曦等: "干酪乳杆菌的益生特性及在食品中应用研究进展", 《农产品加工》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113444675A (en) * | 2021-09-01 | 2021-09-28 | 山东向日葵生物工程有限公司 | Lactobacillus casei SF-L-12, plant beverage thereof and application thereof in ovary maintenance |
| CN115181711A (en) * | 2022-09-14 | 2022-10-14 | 中国农业科学院北京畜牧兽医研究所 | Human milk bacillus LHM11, microbial inoculum and application |
| CN115181712A (en) * | 2022-09-14 | 2022-10-14 | 中国农业科学院北京畜牧兽医研究所 | Lactobacillus johnsonii LJM20 and microbial inoculum and application thereof |
| CN115181711B (en) * | 2022-09-14 | 2022-12-13 | 中国农业科学院北京畜牧兽医研究所 | Human milk bacillus LHM11, microbial inoculum and application |
| CN115181712B (en) * | 2022-09-14 | 2022-12-13 | 中国农业科学院北京畜牧兽医研究所 | Lactobacillus johnsonii LJM20 and microbial inoculum and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112592871B (en) | 2021-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112592871B (en) | Lactobacillus casei JYLC-374 and application thereof in product for improving male prostate | |
| US6428783B1 (en) | Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men | |
| CN110669697B (en) | Lactobacillus casei for high yield of short-chain fatty acid, culture method and application thereof | |
| CN113337430B (en) | Lactobacillus paracasei NSL0201 and application thereof | |
| CN109055278B (en) | A kind of Lactobacillus rhamnosus JYLR-005 and its hypoglycemic product and application | |
| CN112430553A (en) | Lactobacillus reuteri SF-L-25 with helicobacter pylori inhibiting function and application thereof | |
| CN113943687B (en) | Lactobacillus reuteri JYLB-291 for improving ulcerative colitis and application thereof | |
| AU2020103929A4 (en) | Bacillus coagulans strain BACO-17 with high germination rate in the intestines and its uses for promoting gastrointestinal health | |
| CN112458007A (en) | Lactobacillus crispatus for preventing and/or treating diseases related to genital tract flora disorder | |
| CN114107121B (en) | Bacillus coagulans and application thereof in treatment of alcoholic liver disease | |
| CN114908020B (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application of lactobacillus plantarum in edible herbal enzyme product | |
| CN114574390A (en) | Bifidobacterium longum subspecies of infant for relieving colitis and application | |
| CN106967645A (en) | The lactobacillus acidophilus of one plant height production tannase and its application in preventing and treating grice diarrhoea | |
| CN116083325B (en) | Lactobacillus rhamnosus for improving helicobacter pylori related gastrointestinal diseases and application thereof | |
| CN111493261A (en) | Probiotic solid beverage for relieving or treating constipation symptom | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN109983115B (en) | Lactobacillus gasseri and culture method and application thereof | |
| CN116144536A (en) | Composite probiotics fermentation composition for improving male sperm motility and application | |
| CN116555076A (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| CN110973247A (en) | Lactobacillus casei Haidilao-1-containing lactobacillus beverage and preparation method thereof | |
| CN113337440B (en) | Lactobacillus salivarius MG-587 and application thereof | |
| CN113337427A (en) | Lactobacillus plantarum HNU082, composition and application thereof | |
| CN113337428A (en) | Lactobacillus plantarum HNU082 and application thereof | |
| CN114836349B (en) | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof | |
| CN116970512A (en) | Lactobacillus plantarum, and culture method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |